MacroGenics (MGNX) Stock Price, News & Analysis

Company Overview

MacroGenics, Inc., headquartered in Rockville, Maryland, is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody–based therapies for the treatment of cancer. Since its founding in 2000, the company has leveraged its proprietary Dual-Affinity Re-Targeting (DART) platform to engineer multifunctional antibodies designed to direct the immune system against tumor cells. MacroGenics’ research and development efforts emphasize the creation of next-generation immuno-oncology agents, including bispecific antibodies and antibody–drug conjugates, aimed at improving patient outcomes across a range of solid and hematological malignancies.

At the core of MacroGenics’ pipeline is margetuximab, a monoclonal antibody targeting HER2-positive cancers, which has been evaluated in pivotal clinical studies. Beyond margetuximab, the company is advancing multiple DART-based candidates, such as bispecific T-cell engagers that recruit and activate T cells against tumor-associated antigens. In addition, MacroGenics is exploring antibody–drug conjugates that deliver cytotoxic payloads selectively to cancer cells. The company collaborates with larger pharmaceutical partners and research institutions to accelerate development, licensing, and commercialization of its therapeutic candidates worldwide.

MacroGenics operates globally, maintaining strategic partnerships across the United States, Europe, and Asia to facilitate clinical trials and regulatory approvals. The leadership team is helmed by President and Chief Executive Officer Scott Koenig, who brings extensive industry experience in oncology drug development. The company’s management also includes Chief Scientific Officer Derick Mitnaul and Chief Financial Officer Tony Vastola, each contributing specialized expertise in strategic business planning and scientific innovation. Through its integrated approach to antibody engineering and collaborative alliances, MacroGenics aims to deliver transformative cancer therapies to patients in need.

Key Stats

• Today's Range: $1.52 to $1.62
• 50-Day Range: $1.19 to $1.78
• 52-Week Range: $0.99 to $5.77
• Volume: 764,998 shs
• Average Volume: 849,087 shs
• Market Capitalization: $101.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.71
• Consensus Rating: Hold

MacroGenics Stock Analysis - MarketRank™

MacroGenics scored higher than 85% of companies evaluated by MarketBeat, and ranked 161st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

MacroGenics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

MacroGenics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MacroGenics are expected to decrease in the coming year, from ($1.06) to ($2.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MacroGenics is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MacroGenics is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MacroGenics has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.80% of the float of MacroGenics has been sold short.

Short Interest Ratio / Days to Cover

MacroGenics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MacroGenics has recently decreased by 18.26%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MacroGenics does not currently pay a dividend.

Dividend Growth

MacroGenics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.61

Percentage of Shares Shorted

7.80% of the float of MacroGenics has been sold short.

Short Interest Ratio / Days to Cover

MacroGenics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MacroGenics has recently decreased by 18.26%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.64

News Sentiment

MacroGenics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for MacroGenics this week, compared to 7 articles on an average week.

MarketBeat Follows

Only 1 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MacroGenics insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.00% of the stock of MacroGenics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MGNX Stock Analysis - Frequently Asked Questions

How have MGNX shares performed this year?

MacroGenics' stock was trading at $3.25 at the beginning of the year. Since then, MGNX stock has decreased by 50.5% and is now trading at $1.61.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) issued its earnings results on Tuesday, May, 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.04. The biopharmaceutical company had revenue of $13.19 million for the quarter, compared to the consensus estimate of $9.59 million. MacroGenics had a negative net margin of 36.23% and a negative trailing twelve-month return on equity of 59.84%.

How do I buy shares of MacroGenics?

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MacroGenics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MacroGenics investors own include NVIDIA (NVDA), Broadcom (AVGO), Invesco QQQ (QQQ), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MGNX
• CIK: 1125345
• Web: www.macrogenics.com
• Phone: (301) 251-5172
• Fax: 301-251-5321
• Employees: 430
• Year Founded: 2000

Price Target and Rating

• Average Price Target for MacroGenics: $5.71
• High Price Target: $14.00
• Low Price Target: $2.00
• Potential Upside/Downside: +254.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$66.97 million
• Net Margins: -36.23%
• Pretax Margin: -35.62%
• Return on Equity: -59.84%
• Return on Assets: -23.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.28
• Quick Ratio: 3.11

Sales & Book Value

• Annual Sales: $149.96 million
• Price / Sales: 0.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.85 per share
• Price / Book: 0.87

Miscellaneous

• Outstanding Shares: 63,090,000
• Free Float: 54,888,000
• Market Cap: $101.57 million
• Optionable: Optionable
• Beta: 1.59